Health
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the fourth Phase 3 clinical trial DREAMS-3 of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist, has met its primary endpoint. The results demonstrated that, in Chinese pa
About this update from Innovent Biologics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group","length":174,"tagName":"p"}]},{"val":[{"type":"text","content":"DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head comparison with semaglutide in diabetes treatment","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":343,"olType":false},{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Oct. 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the fourth Phase 3 clinical trial DREAMS-3 of mazdutide, a glucagon-like peptide-1 (GLP-1) and glucagon (GCG) dual receptor agonist, has met its primary endpoint. The results demonstrated that, in Chinese patients with type 2 diabetes (T2D) and obesity, mazdutide showed superior efficacy to semaglutide on the primary endpoint—the proportion of participants achieving HbA1c < 7.0% and ≥10% body weight reduction from baseline at week 32 (48.0 vs. 21.0%, p<0.0001). In addition, at week 32, the mean change in HbA1c from baseline was −2.03% in the mazdutide group and −1.84% in semaglutide group, respectively, and the mean percentage weight reduction from baseline was 10.29% in the mazdutide group and 6.00% in the semaglutide group, respectively (both p<0.05). During the study, the overall safety profile of mazdutide was consistent with previous clinical studies, with no new safety signals identified. Gastrointestinal symptoms were the most common adverse events, mostly mild to moderate in severity.","length":1382,"tagName":"p"},{"type":"text","content":"Professor Linong Ji, the Principal Investigator of the DREAMS-3, Peking University People's Hospital, stated: "Diabetes and obesity share similar epidemic trends. Among the vast population with T2D in China, the proportion of those with comorbid obesity has been increasing. Previous studies have indicated that, compared with non-obese patients with diabete...